In most cancers, the activation of NF‐κB is enhanced, and this enhancement in NF‐κB activation is often due to increased stimuli of the NF‐κB pathway, such as increased TNFα and IL‐1 in the tumor microenvironment.281, 282. This evidence concerns the gene IL1B and cancer.